GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » Gross Profit

RDPTF (Radiopharm Theranostics) Gross Profit : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics Gross Profit?

Radiopharm Theranostics's gross profit for the six months ended in Dec. 2023 was $0.00 Mil. Radiopharm Theranostics's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Radiopharm Theranostics's gross profit for the six months ended in Dec. 2023 was $0.00 Mil. Radiopharm Theranostics's Revenue for the six months ended in Dec. 2023 was $0.00 Mil. Therefore, Radiopharm Theranostics's Gross Margin % for the quarter that ended in Dec. 2023 was N/A%.

Radiopharm Theranostics had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Radiopharm Theranostics Gross Profit Historical Data

The historical data trend for Radiopharm Theranostics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Gross Profit Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24
Gross Profit
0.01 0.20 0.20

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Gross Profit Get a 7-Day Free Trial - 0.20 - - -

Competitive Comparison of Radiopharm Theranostics's Gross Profit

For the Biotechnology subindustry, Radiopharm Theranostics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radiopharm Theranostics's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Gross Profit distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Gross Profit falls into.



Radiopharm Theranostics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Radiopharm Theranostics's Gross Profit for the fiscal year that ended in Jun. 2024 is calculated as

Gross Profit (A: Jun. 2024 )=Revenue - Cost of Goods Sold
=0.199 - 0
=0.20

Radiopharm Theranostics's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Radiopharm Theranostics's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Radiopharm Theranostics  (OTCPK:RDPTF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Radiopharm Theranostics had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Radiopharm Theranostics Gross Profit Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiopharm Theranostics Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics Headlines

From GuruFocus

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire 10-19-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 07-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-30-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-20-2022